Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

FDA Approves Pfizer’s Talzenna for Some Patients With BRCA-Mutated Breast Cancer

By Catherine Sbeglia | October 17, 2018

Earlier this week, the FDA approved Pfizer’s Pfizer’s PARP inhibitor Talzenna (talazoparib) for use in patients with germline BRCA-mutated, HER2‑negative locally advanced or metastatic breast cancer. The agency stated that patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.

Approval was supported by efficacy and safety data from the EMBRACA, an open‑label trial randomizing 431 patients (2:1) with gBRCAm HER2‑negative locally advanced or metastatic breast cancer to receive talazoparib (1 mg) or physician’s choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). The results demonstrated that Talzenna promoted progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by blinded independent central review. 

Pfizer gained rights to Talzenna in 2016 as part of its $14-billion acquisition of Medivation. According to BioMarin Pharmaceutical, which had licensed rights to the therapy to Medivation in a deal valued at as much as $570 million, BioMarin will receive a $15-million milestone payment from Pfizer due to Talzenna’s recent approval. 

FDA also approved the BRACAnalysis CDx test (Myriad Genetic Laboratories, Inc.) to identify patients with breast cancer with deleterious or suspected deleterious gBRCAm who are eligible for talazoparib. The effectiveness of the BRACAnalysis CDx test was based on the EMBRACA trial population for whom deleterious or suspected deleterious gBRCAm status was confirmed with either prospective or retrospective testing with BRACAnalysis CDx.

Talzenna is currently under European agency review for the treatment of patients with metastatic breast cancer with an inherited BRCA mutation.

(Sources: The U.S. Food and Drug Administration; Pfizer; Globe Newswire) 

Related Articles Read More >

Endevica
Investigational drug promises to reverse wasting syndrome in cancer patients
Nodular melanoma
BioNTech and Moderna set their sights on treating cancer
4D Path
4D Path and University of Leeds extend partnership to validate oncology platform
Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards